EZH2 and myelodysplastic syndrome: Genomic deletion and loss-of-function mutations of EZH2/KMT6A were frequently found in MDS and other myeloid malignancies (62), whereas its gain-of-function mutations occur in 10–20% of B-cell lymphoma patients (63–65).